PL1922335T3 - Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II - Google Patents

Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II

Info

Publication number: PL1922335T3
Authority: PL; Poland
Prior art keywords: molecules; tumour; present; relates; hla
Prior art date: 2005-09-05

Application number

PL06791838T

Other languages

English (en)

Inventor

Jörn Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2006-09-05

Publication date

2010-05-31

2006-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2010-05-31 Publication of PL1922335T3 publication Critical patent/PL1922335T3/pl

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
210000000265 leukocyte Anatomy 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
230000001024 immunotherapeutic effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
239000008186 active pharmaceutical agent Substances 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL06791838T 2005-09-05 2006-09-05 Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II PL1922335T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (en)	2005-09-05	2005-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
PCT/EP2006/008642 WO2007028574A2 (en)	2005-09-05	2006-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
EP06791838A EP1922335B1 (en)	2005-09-05	2006-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules

Publications (1)

Publication Number	Publication Date
PL1922335T3 true PL1922335T3 (pl)	2010-05-31

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PL07007915T PL1806359T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL07007914T PL1806358T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL05019254T PL1760088T3 (pl)	2005-09-05	2005-09-05	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL09011319T PL2135878T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami HLA klasy II
PL06791838T PL1922335T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami antygenów leukocytów ludzkich (HLA) klasy II

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
PL07007915T PL1806359T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL07007914T PL1806358T3 (pl)	2005-09-05	2005-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
PL05019254T PL1760088T3 (pl)	2005-09-05	2005-09-05	Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
PL09011319T PL2135878T3 (pl)	2005-09-05	2006-09-05	Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami HLA klasy II

Country Status (23)

Country	Link
US (6)	US10196432B2 (pl)
EP (6)	EP1806358B1 (pl)
JP (1)	JP5627180B2 (pl)
KR (3)	KR101386790B1 (pl)
CN (3)	CN105440119A (pl)
AT (5)	ATE461214T1 (pl)
AU (2)	AU2006289290B2 (pl)
BR (1)	BRPI0615462A2 (pl)
CA (2)	CA2929252A1 (pl)
CY (5)	CY1107973T1 (pl)
DE (4)	DE602005020046D1 (pl)
DK (5)	DK1760088T3 (pl)
EA (1)	EA013876B1 (pl)
ES (5)	ES2341802T3 (pl)
HK (1)	HK1220709A1 (pl)
HR (2)	HRP20100128T1 (pl)
NO (1)	NO340870B1 (pl)
NZ (2)	NZ588813A (pl)
PL (5)	PL1806359T3 (pl)
PT (5)	PT1806358E (pl)
SI (5)	SI1760088T1 (pl)
UA (1)	UA98295C2 (pl)
WO (1)	WO2007028574A2 (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602005020046D1 (de) *	2005-09-05	2010-04-29	Immatics Biotechnologies Gmbh	Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
NZ582823A (en)	2007-07-27	2012-04-27	Immatics Biotechnologies Gmbh	Composition of tumour-associated peptides and related anti-cancer vaccine
HUE025636T2 (en) *	2007-07-27	2016-04-28	Immatics Biotechnologies Gmbh	Novel immunogenic epitopes for immunotherapy
RS54204B1 (sr)	2007-07-27	2015-12-31	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv tumora mozga
UA100127C2 (ru) *	2007-08-20	2012-11-26	Онкотерапи Саенс, Инк.	Пептид cdh3 и лекарственное средство, содержащее его
EP3085707B1 (en)	2007-11-01	2019-02-27	Mayo Foundation for Medical Education and Research	Hla-dr binding peptides and their uses
ME02267B (me)	2008-03-27	2016-04-28	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv tumora nervnih ćelija i mozga
EP2113253B1 (en)	2008-04-30	2010-03-31	Immatics Biotechnologies GmbH	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
PT2119726E (pt)	2008-05-14	2015-03-30	Immatics Biotechnologies Gmbh	Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
ES2536465T3 (es) *	2008-10-01	2015-05-25	Immatics Biotechnologies Gmbh	Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
DK2623517T3 (en)	2009-01-28	2015-11-23	Ind Tech Res Inst	Urine and serum biomarkers associated with diabetic nephropathy
US9023802B2 (en)	2009-12-14	2015-05-05	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
SG191154A1 (en)	2010-12-14	2013-07-31	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2012129514A1 (en) *	2011-03-23	2012-09-27	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
TWI714869B (zh) *	2013-08-05	2021-01-01	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
ES2900004T3 (es)	2013-08-05	2022-03-15	Immatics Biotechnologies Gmbh	Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr)	2014-05-09	2019-12-13	Immatics Biotechnologies Gmbh	Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr)	2014-12-23	2021-04-07	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
IL301919A (en)	2015-03-27	2023-06-01	Immatics Biotechnologies Gmbh	Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
IL292697A (en) *	2015-06-19	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and their combination for use in immunotherapy and methods for creating supports for use against pancreatic cancer and other types of cancer
IL308735A (en)	2015-07-01	2024-01-01	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt)	2015-07-06	2021-01-06	Immatics Biotechnologies Gmbh	Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
GB201512369D0 (en)	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL292864A (en)	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
PH12022551111A1 (en)	2015-10-05	2023-08-23	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY196837A (en)	2015-12-11	2023-05-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
JP7114477B2 (ja)	2015-12-16	2022-08-08	グリットストーンバイオインコーポレイテッド	新生抗原の特定、製造、および使用
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
PE20181583A1 (es)	2016-03-01	2018-10-04	Immatics Biotechnologies Gmbh	Peptido recombinante derivado de la proteina duoxa2
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
SG11201808196UA (en) *	2016-03-31	2018-10-30	Neon Therapeutics Inc	Neoantigens and methods of their use
SG10202110335PA (en)	2016-04-06	2021-10-28	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
MA43477A1 (fr)	2016-04-21	2019-05-31	Immatics Biotechnologies Gmbh	Immunothérapie contre le mélanome et d'autres cancers
CR20200608A (es)	2016-04-21	2021-01-20	Immatics Biotechnologies Gmbh	INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
ES2987986T3 (es) *	2016-06-10	2024-11-18	Gadeta B V	Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
TW202304970A (zh)	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
EA201991444A1 (ru)	2017-01-27	2019-12-30	Имматикс Байотекнолоджиз Гмбх	Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
AU2018212584B2 (en)	2017-01-27	2020-12-10	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2018138257A1 (en)	2017-01-27	2018-08-02	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TWI723247B (zh) *	2017-02-06	2021-04-01	中央研究院	重組蛋白及其用途
TW201841937A (zh)	2017-04-10	2018-12-01	德商英麥提克生物技術股份有限公司	用於白血病和其他癌症免疫治療的新穎肽和肽組合物
TW201841934A (zh)	2017-04-10	2018-12-01	德商英麥提克生物技術股份有限公司	用於治療癌症免疫治療的新穎肽及其肽組合物
MA49123A (fr)	2017-04-10	2020-03-25	Immatics Biotechnologies Gmbh	Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
CR20210160A (es)	2017-04-10	2021-04-26	Immatics Biotechnologies Gmbh	Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
KR20200026898A (ko)	2017-07-07	2020-03-11	이매틱스 바이오테크놀로지스 게엠베하	Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
EP3684196B1 (en)	2017-09-18	2024-09-04	S & P Ingredient Development, LLC	Low sodium salt substitute with potassium chloride
CN111465989B (zh)	2017-10-10	2024-06-25	磨石生物公司	使用热点进行的新抗原鉴别
AU2018373154B2 (en)	2017-11-22	2025-08-07	Seattle Project Corp.	Reducing junction epitope presentation for neoantigens
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
KR20200119840A (ko)	2018-02-09	2020-10-20	이매틱스 유에스 인코포레이티드	T 세포의 제조 방법
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
IL276839B1 (en) *	2018-02-27	2026-05-01	Gritstone Bio Inc	Neoantigen identification using pan-allelic models
EP3539562A1 (en) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immunotherapeutic peptides
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en)	2018-09-17	2024-04-02	Immatics Biotechnologies Gmbh	B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
AU2020286756A1 (en)	2019-06-06	2022-01-27	Immatics Biotechnologies Gmbh	Sorting with counter selection using sequence similar peptides
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
WO2021019472A1 (en) *	2019-07-30	2021-02-04	University Health Network	T cell receptors and methods of use thereof
EP3827840A1 (en)	2019-11-29	2021-06-02	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	Teipp peptide variant and uses thereof
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2024077601A1 (en) *	2022-10-14	2024-04-18	Guangdong Tcrcure Biopharma Technology Co., Ltd.	Peptide vaccines against glioma and uses thereof
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (pl) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en)	1978-12-22	1990-04-30	Biogen Nv	Process for obtaining recombinant dnk molecules
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en)	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
EP0636175A1 (en) *	1992-04-03	1995-02-01	La Jolla Cancer Research Foundation	Decorin fragments and methods of inhibiting cell regulatory factors
EP0671926B1 (en) *	1992-08-11	2002-11-13	President And Fellows Of Harvard College	Immunomodulatory peptides
EP0725799A1 (en) *	1993-10-29	1996-08-14	Dana-Farber Cancer Institute, Inc.	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
WO1996003144A1 (en)	1994-07-27	1996-02-08	The Council Of The Queensland Institute Of Medical Research	Polyepitope vaccines
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
US6805861B2 (en)	1996-01-17	2004-10-19	Imperial College Innovations Limited	Immunotherapy using cytotoxic T lymphocytes (CTL)
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
AU6241698A (en) *	1997-01-21	1998-08-07	Human Genome Sciences, Inc.	Tace-like and matrilysin-like polypeptides
US6316213B1 (en)	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
EP1023445B1 (de)	1997-10-15	2005-08-17	Pharis Biotec GmbH	Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
EP1290217A2 (en) *	2000-02-04	2003-03-12	Aeomica, Inc.	Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2002008765A2 (en) *	2000-07-26	2002-01-31	Stanford University	Basal cell markers in breast cancer and uses thereof
WO2002050103A2 (en)	2000-12-20	2002-06-27	Glaxosmithkline Biologicals S.A.	Tumour-related antigens
AU2002303219A1 (en)	2001-03-30	2002-10-15	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
AU2002322280A1 (en) *	2001-06-21	2003-01-21	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2005500059A (ja) *	2001-08-13	2005-01-06	ダナ−ファーバーキャンサーインスティテュートインク．	ペリオスチンに基づく診断アッセイ法
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
WO2003030836A2 (en) *	2001-10-12	2003-04-17	Case Western Reserve University	Neuronal regeneration
WO2003068940A2 (en) *	2002-02-14	2003-08-21	Curagen Corporation	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2004014867A2 (en) *	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
CA2500687A1 (en) *	2002-10-02	2004-04-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP1560597A4 (en) *	2002-10-29	2007-06-27	Pharmacia Corp	DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
JP2007504842A (ja) *	2003-05-29	2007-03-08	ミレニアムファーマシューティカルズ，インコーポレイテッド	乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
EP1646648A2 (en) *	2003-07-15	2006-04-19	Genova Ltd.	Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
DE602005020046D1 (de) *	2005-09-05	2010-04-29	Immatics Biotechnologies Gmbh	Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) *	2005-09-05	2009-12-31	Immatics Biotechnologies Gmbh	S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
EP1795599A1 (en) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Methods for generating antigen-specific effector T cells

2005
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Expired - Lifetime
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Expired - Lifetime
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Expired - Lifetime
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
2006
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en not_active Ceased
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
2007
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
JP5627180B2 (ja)	2014-11-19
EA013876B1 (ru)	2010-08-30
WO2007028574A2 (en)	2007-03-15
ATE461214T1 (de)	2010-04-15
EP2135878B1 (en)	2011-11-09
ES2341802T3 (es)	2010-06-28
CA2929252A1 (en)	2007-03-15
PT2135878E (pt)	2012-01-05
PL1806358T3 (pl)	2010-08-31
US10196432B2 (en)	2019-02-05
SI1806359T1 (sl)	2010-06-30
EA200800677A1 (ru)	2008-08-29
KR101386790B1 (ko)	2014-04-21
EP1760088A1 (en)	2007-03-07
EP1806358A3 (en)	2007-10-03
AU2010236029B2 (en)	2012-06-28
UA98295C2 (ru)	2012-05-10
PL1760088T3 (pl)	2008-10-31
PL1806359T3 (pl)	2010-08-31
PT1922335E (pt)	2010-03-03
CY1110187T1 (el)	2015-01-14
DE602005005196D1 (de)	2008-04-17
HK1183678A1 (en)	2014-01-03
US20080206216A1 (en)	2008-08-28
CN101287754A (zh)	2008-10-15
HRP20110981T1 (hr)	2012-02-29
EP1922335A2 (en)	2008-05-21
ES2373907T3 (es)	2012-02-10
DK2135878T3 (da)	2012-02-27
ATE451388T1 (de)	2009-12-15
CY1109849T1 (el)	2014-09-10
HRP20100128T1 (hr)	2010-04-30
US7833970B2 (en)	2010-11-16
CN103059104A (zh)	2013-04-24
PT1806359E (pt)	2010-05-25
CY1112186T1 (el)	2015-12-09
DE602005020047D1 (de)	2010-04-29
CN101287754B (zh)	2013-02-13
ATE461215T1 (de)	2010-04-15
SI1922335T1 (sl)	2010-04-30
NO20081683L (no)	2008-04-04
WO2007028574A9 (en)	2008-05-02
PT1760088E (pt)	2008-05-14
KR20080052643A (ko)	2008-06-11
CY1110051T1 (el)	2015-01-14
NO340870B1 (no)	2017-07-03
US7807642B2 (en)	2010-10-05
AU2006289290B2 (en)	2010-11-25
SI1806358T1 (sl)	2010-06-30
US20080206218A1 (en)	2008-08-28
HK1220709A1 (zh)	2017-05-12
CA2621389C (en)	2016-07-19
PL2135878T3 (pl)	2012-06-29
ES2337399T3 (es)	2010-04-23
ES2302546T3 (es)	2008-07-16
ATE388164T1 (de)	2008-03-15
CA2621389A1 (en)	2007-03-15
AU2010236029A1 (en)	2010-11-18
US20160115212A1 (en)	2016-04-28
EP1806358B1 (en)	2010-03-17
DK1760088T3 (da)	2008-06-09
US7833969B2 (en)	2010-11-16
DE602006011030D1 (de)	2010-01-21
KR101386827B1 (ko)	2014-04-17
US10618945B2 (en)	2020-04-14
SI2135878T1 (sl)	2012-03-30
CY1107973T1 (el)	2013-09-04
EP1806359B1 (en)	2010-03-17
WO2007028574A3 (en)	2007-05-24
KR20130019034A (ko)	2013-02-25
CN103059104B (zh)	2015-10-28
SI1760088T1 (sl)	2008-06-30
US20080206217A1 (en)	2008-08-28
PT1806358E (pt)	2010-05-28
DE602005005196T2 (de)	2008-06-26
EP1760088B1 (en)	2008-03-05
DK1922335T3 (da)	2010-04-19
KR101386355B1 (ko)	2014-04-17
DK1806359T3 (da)	2010-06-14
ATE532795T1 (de)	2011-11-15
EP2138509A1 (en)	2009-12-30
EP2135878A1 (en)	2009-12-23
KR20130019033A (ko)	2013-02-25
NZ566104A (en)	2011-04-29
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
US20080207520A1 (en)	2008-08-28
ES2341295T3 (es)	2010-06-17
EP1806359A1 (en)	2007-07-11
NZ588813A (en)	2011-06-30
JP2010502173A (ja)	2010-01-28
DK1806358T3 (da)	2010-06-28
EP1806358A2 (en)	2007-07-11
AU2006289290A1 (en)	2007-03-15
US20100040590A1 (en)	2010-02-18
DE602005020046D1 (de)	2010-04-29
EP1922335B1 (en)	2009-12-09

Publication	Publication Date	Title
SI1922335T1 (sl)	2010-04-30	S tumorjem povezan peptid, ki se vedno veĹľe na molekule humanega levkocitnega antigena (HLA) razreda II
SI1922334T1 (sl)	2011-04-29	S tumorjem povezani peptidi, ki se veĹľejo na molekule antigena humanih levkocitov (HLA), razreda I in II, ter ustrezno cepivo proti raku
SI1794190T1 (sl)	2009-12-31	Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope